A phase 1 trial of Actimab-A in combination with CLAG-M for patients with relapsed or refractory acute myeloid leukemia (AML).

Trial Profile

A phase 1 trial of Actimab-A in combination with CLAG-M for patients with relapsed or refractory acute myeloid leukemia (AML).

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Lintuzumab Ac-225 (Primary) ; Cladribine; Cytarabine; Filgrastim; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Feb 2018 According to a Actinium Pharmaceuticals media release, this trial will be led by Dr. Sameem Abedin.
    • 12 Feb 2018 According to a Actinium Pharmaceuticals media release, an Investigational New Drug (IND) application has been submitted with the U.S. Food and Drug Administration (FDA) to initiate this trial.
    • 08 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top